Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria
Conditions
- Chronic Spontaneous Urticaria
- Chronic Urticaria, Idiopathic
Interventions
- DRUG: omalizumab 300 mg every four weeks
- DRUG: omalizumab 300 mg every six weeks
Sponsor
Simon Francis Thomsen
Collaborators